Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

被引：56

作者：

Alva, A. ^{[1
]}

Csoszi, T. ^{[2
]}

Ozguroglu, M. ^{[3
]}

Matsubara, N. ^{[4
]}

Geczi, L. ^{[5
]}

Cheng, S. Y-S. ^{[6
]}

Fradet, Y. ^{[7
]}

Oudard, S. ^{[8
]}

Vulsteke, C. ^{[9
]}

Morales Barrera, R. ^{[10
]}

Flechon, A. ^{[11
]}

Gunduz, S. ^{[12
]}

Loriot, Y. ^{[13
]}

Rodriguez-Vida, A. ^{[14
]}

Mamtani, R. ^{[15
]}

Yu, E. Y. ^{[16
]}

Nam, K. ^{[17
]}

Imai, K. ^{[18
]}

Moreno, B. H. ^{[19
]}

Powles, T. B. ^{[20
]}

机构：

[1] Univ Michigan, Hematol Oncol, Ann Arbor, MI 48109 USA

[2] Hetenyi G Korhaz Onkol Kozpont, Oncol, Szolnok, Hungary

[3] Istanbul Univ Cerrahpasa, Med Oncol, Cerrahpasa Sch Med, Istanbul, Turkey

[4] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[5] Natl Inst Oncol Hungary, Med Oncol, Budapest, Hungary

[6] Sunnybrook Odette Canc Ctr, Oncol, Toronto, ON, Canada

[7] Univ Laval, CHU Quebec, Surg Urol, Quebec City, PQ, Canada

[8] Hop European George Pompidou, Immunotherapie & Traitement Antiangiogen Pathol C, Paris, France

[9] Ctr Oncol Res CORE, Antwerp, Belgium

[10] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[11] Ctr Leon Berard, Dept Med Oncol, Rhones Alpes, France

[12] Mem Antalya Hosp, Dept Med Oncol, Antalya, Turkey

[13] Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[14] Hosp del Mar, Dept Med Oncol, Barcelona, Spain

[15] Univ Penn, Abramson Canc Ctr, Hematol Oncol, Philadelphia, PA 19104 USA

[16] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[17] Merck & Co Inc, Stat, Kenilworth, NJ USA

[18] Merck & Co Inc, Clin Res Oncol Dept, Kenilworth, NJ USA

[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[20] Queen Mary Univ London, Barts Canc Inst, Dept Med Oncol, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA23

引用

页码：S1155 / S1155

页数：1

共 50 条

[1] Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361
Ozyilkan, Ozgur
McDermott, Raymond S.
Juan-Fita, Maria Jose
Semenov, Andrey
Alekseev, Boris
Berger, Raanan
Bae, Woo Kyun
Danchaivijitr, Pongwut
Lin, Jianxin
Bavle, Abhishek Amar
Imai, Kentaro
Arslan, Cagatay
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Powles, Thomas
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y-S
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Barrera, Rafael Morales
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai
LANCET ONCOLOGY, 2021, 22 (07): : 931 - 945
[3] Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).
Alva, Ajjai Shivaram
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[4] Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).
Ozguroglu, Mustafa
Alva, Ajjai Shivaram
Csoszi, Tibor
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[5] Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
Powles, Thomas
Alva, Ajjai Shivaram
Ozguroglu, Mustafa
O'Donnell, Peter H.
Loriot, Yohann
Csoszi, Tibor
Vuky, Jacqueline
Morales-Barrera, Rafael
Plimack, Elizabeth R.
Matsubara, Nobuaki
Fradet, Yves
Geczi, Lajos
Gunduz, Seyda
Mamtani, Ronac
Bajorin, Dean F.
Liu, Chih-Chin
Imai, Kentaro
Moreno, Blanca Homet
Bellmunt, Joaquim
Balar, Arjun Vasant
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[6] 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.
Powles, Thomas
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai Shivaram
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[7] Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer
Powles, Thomas
Gschwend, Juergen E.
Loriot, Yohann
Bellmunt, Joaquim
Geczi, Lajos
Vulsteke, Christof
Abdelsalam, Mahmoud
Gafanov, Rustem
Bae, Woo Kyun
Revesz, Janos
Yamamoto, Yoshiaki
Anido, Urbano
Su, Wen-Pin
Fleming, Mark T.
Markus, Maurice
Feng, Dai
Poehlein, Christian Heinrich
Alva, Ajjai
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.
Csoszi, Tibor
Powles, Thomas
Alva, Ajjai Shivaram
Castellano, Daniel E.
Ozguroglu, Mustafa
O'Donnell, Peter H.
Loriot, Yohann
Hahn, Noah M.
Flechon, Aude
Rodriguez-Vida, Alejo
De Wit, Ronald
Cheng, Susanna Y.
Oudard, Stephane
Vulsteke, Christof
Yu, Evan Y.
Lin, Jianxin
Imai, Kentaro
Moreno, Blanca Homet
Balar, Arjun Vasant
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[9] Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials
Giannatempo, Patrizia
Machiels, Jean-Pascal H.
Sassa, Naoto
Arija, Jose Angel Arranz
Fujii, Yasuhisa
Su, Wen-Pin
Keam, Bhumsuk
Culine, Stephane
Shen, Ying-Chun
Munoz-Langa, Jose
Sarid, David Leonid
Aarts, Maureen J. B.
Calabro, Fabio
Rosenbaum, Eli
Goldman, Olesya
Moreno, Blanca Homet
Bavle, Abhishek Amar
Xu, Jin Zhi
Rha, Sun Young
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] First-line treatment for locally advanced or metastatic urothelial carcinoma: a randomized controlled phase III study comparing pembrolizumab with and without platinum-based combination chemotherapy and chemotherapy alone in patients with advanced or metastatic urothelial carcinoma (Keynote-361) AB 54/16 of AUO
Rexer, H.
Ohlmann, C. -H.
Retz, M.
AKTUELLE UROLOGIE, 2018, 49 (01) : 21 - 22

← 1 2 3 4 5 →